Molecular mapping of the thrombin-heparin cofactor II complex

Yolanda M Fortenberry, Herbert C. Whinna, Holly R. Gentry, Timothy Myles, Lawrence L K Leung, Frank C. Church

Research output: Contribution to journalArticle

Abstract

We used 55 Ala-scanned recombinant thrombin molecules to define residues important for inhibition by the serine protease inhibitor (serpin) heparin cofactor II (HCII) in the absence and presence off glycosaminoglycans. We verified the importance of numerous basic residues in anion-binding exosite-1 (exosite-1) and found 4 additional residues, Gln24, Lys65, His66, and Tyr71 (using the thrombin numbering system), that were resistant to HCII inhibition with and without glycosaminoglycans. Inhibition rate constants for these exosite-1 (Q24A, K65A, H66A, Y71A) thrombin mutants (0.02-0.38 × 108 M-1 min-1 for HCII-heparin when compared with 2.36 × 108 M-1 min-1 with wild-type thrombin and 0.03-0.53 × 108 M-1 min-1 for HCII-denaatan sulfate when compared with 5.23 × 108 M-1 min-1 with wild-type thrombin) confirmed that the structural integrity of thrombin exosite-1 is critical for optimal HCII-thrombin interactions in the presence of glycosaminoglycans. However, our results are also consistent for HCII-glycosaminoglycan-thrombin ternary complex formation. Ten residues surrounding the active site of thrombin were implicated in HCII interactions. Four mutants (Asp51, Lys 52, Lys145/ Thr147/Trp148, Asp 234) showed normal increased rates of inhibition by HCII-glycosaminoglycans, whereas four mutants (Trp50, Glu 202, Glu229, Arg233) remained resistant to inhibition by HCII with glycosaminoglycans. Using 11 exosite-2 thrombin mutants with 20 different mutated residues, we saw no major perturbations of HCII-glycosaminoglycan inhibition reactions. Collectively, our results support a "double bridge" mechanism for HCII inhibition of thrombin in the presence of glycosaminoglycans, which relies in part on ternary complex formation but is primarily dominated by an allosteric process involving contact of the "hirudin-like" domain of HCII with thrombin exosite-1.

Original languageEnglish (US)
Pages (from-to)43237-43244
Number of pages8
JournalJournal of Biological Chemistry
Volume279
Issue number41
DOIs
StatePublished - Oct 8 2004
Externally publishedYes

Fingerprint

Heparin Cofactor II
Thrombin
Glycosaminoglycans
Hirudins
Numbering systems
Serine Proteinase Inhibitors
Structural integrity
Sulfates

ASJC Scopus subject areas

  • Biochemistry

Cite this

Fortenberry, Y. M., Whinna, H. C., Gentry, H. R., Myles, T., Leung, L. L. K., & Church, F. C. (2004). Molecular mapping of the thrombin-heparin cofactor II complex. Journal of Biological Chemistry, 279(41), 43237-43244. https://doi.org/10.1074/jbc.M406716200

Molecular mapping of the thrombin-heparin cofactor II complex. / Fortenberry, Yolanda M; Whinna, Herbert C.; Gentry, Holly R.; Myles, Timothy; Leung, Lawrence L K; Church, Frank C.

In: Journal of Biological Chemistry, Vol. 279, No. 41, 08.10.2004, p. 43237-43244.

Research output: Contribution to journalArticle

Fortenberry, YM, Whinna, HC, Gentry, HR, Myles, T, Leung, LLK & Church, FC 2004, 'Molecular mapping of the thrombin-heparin cofactor II complex', Journal of Biological Chemistry, vol. 279, no. 41, pp. 43237-43244. https://doi.org/10.1074/jbc.M406716200
Fortenberry, Yolanda M ; Whinna, Herbert C. ; Gentry, Holly R. ; Myles, Timothy ; Leung, Lawrence L K ; Church, Frank C. / Molecular mapping of the thrombin-heparin cofactor II complex. In: Journal of Biological Chemistry. 2004 ; Vol. 279, No. 41. pp. 43237-43244.
@article{25faaedc3c294a2a9076f6c85332322d,
title = "Molecular mapping of the thrombin-heparin cofactor II complex",
abstract = "We used 55 Ala-scanned recombinant thrombin molecules to define residues important for inhibition by the serine protease inhibitor (serpin) heparin cofactor II (HCII) in the absence and presence off glycosaminoglycans. We verified the importance of numerous basic residues in anion-binding exosite-1 (exosite-1) and found 4 additional residues, Gln24, Lys65, His66, and Tyr71 (using the thrombin numbering system), that were resistant to HCII inhibition with and without glycosaminoglycans. Inhibition rate constants for these exosite-1 (Q24A, K65A, H66A, Y71A) thrombin mutants (0.02-0.38 × 108 M-1 min-1 for HCII-heparin when compared with 2.36 × 108 M-1 min-1 with wild-type thrombin and 0.03-0.53 × 108 M-1 min-1 for HCII-denaatan sulfate when compared with 5.23 × 108 M-1 min-1 with wild-type thrombin) confirmed that the structural integrity of thrombin exosite-1 is critical for optimal HCII-thrombin interactions in the presence of glycosaminoglycans. However, our results are also consistent for HCII-glycosaminoglycan-thrombin ternary complex formation. Ten residues surrounding the active site of thrombin were implicated in HCII interactions. Four mutants (Asp51, Lys 52, Lys145/ Thr147/Trp148, Asp 234) showed normal increased rates of inhibition by HCII-glycosaminoglycans, whereas four mutants (Trp50, Glu 202, Glu229, Arg233) remained resistant to inhibition by HCII with glycosaminoglycans. Using 11 exosite-2 thrombin mutants with 20 different mutated residues, we saw no major perturbations of HCII-glycosaminoglycan inhibition reactions. Collectively, our results support a {"}double bridge{"} mechanism for HCII inhibition of thrombin in the presence of glycosaminoglycans, which relies in part on ternary complex formation but is primarily dominated by an allosteric process involving contact of the {"}hirudin-like{"} domain of HCII with thrombin exosite-1.",
author = "Fortenberry, {Yolanda M} and Whinna, {Herbert C.} and Gentry, {Holly R.} and Timothy Myles and Leung, {Lawrence L K} and Church, {Frank C.}",
year = "2004",
month = "10",
day = "8",
doi = "10.1074/jbc.M406716200",
language = "English (US)",
volume = "279",
pages = "43237--43244",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "41",

}

TY - JOUR

T1 - Molecular mapping of the thrombin-heparin cofactor II complex

AU - Fortenberry, Yolanda M

AU - Whinna, Herbert C.

AU - Gentry, Holly R.

AU - Myles, Timothy

AU - Leung, Lawrence L K

AU - Church, Frank C.

PY - 2004/10/8

Y1 - 2004/10/8

N2 - We used 55 Ala-scanned recombinant thrombin molecules to define residues important for inhibition by the serine protease inhibitor (serpin) heparin cofactor II (HCII) in the absence and presence off glycosaminoglycans. We verified the importance of numerous basic residues in anion-binding exosite-1 (exosite-1) and found 4 additional residues, Gln24, Lys65, His66, and Tyr71 (using the thrombin numbering system), that were resistant to HCII inhibition with and without glycosaminoglycans. Inhibition rate constants for these exosite-1 (Q24A, K65A, H66A, Y71A) thrombin mutants (0.02-0.38 × 108 M-1 min-1 for HCII-heparin when compared with 2.36 × 108 M-1 min-1 with wild-type thrombin and 0.03-0.53 × 108 M-1 min-1 for HCII-denaatan sulfate when compared with 5.23 × 108 M-1 min-1 with wild-type thrombin) confirmed that the structural integrity of thrombin exosite-1 is critical for optimal HCII-thrombin interactions in the presence of glycosaminoglycans. However, our results are also consistent for HCII-glycosaminoglycan-thrombin ternary complex formation. Ten residues surrounding the active site of thrombin were implicated in HCII interactions. Four mutants (Asp51, Lys 52, Lys145/ Thr147/Trp148, Asp 234) showed normal increased rates of inhibition by HCII-glycosaminoglycans, whereas four mutants (Trp50, Glu 202, Glu229, Arg233) remained resistant to inhibition by HCII with glycosaminoglycans. Using 11 exosite-2 thrombin mutants with 20 different mutated residues, we saw no major perturbations of HCII-glycosaminoglycan inhibition reactions. Collectively, our results support a "double bridge" mechanism for HCII inhibition of thrombin in the presence of glycosaminoglycans, which relies in part on ternary complex formation but is primarily dominated by an allosteric process involving contact of the "hirudin-like" domain of HCII with thrombin exosite-1.

AB - We used 55 Ala-scanned recombinant thrombin molecules to define residues important for inhibition by the serine protease inhibitor (serpin) heparin cofactor II (HCII) in the absence and presence off glycosaminoglycans. We verified the importance of numerous basic residues in anion-binding exosite-1 (exosite-1) and found 4 additional residues, Gln24, Lys65, His66, and Tyr71 (using the thrombin numbering system), that were resistant to HCII inhibition with and without glycosaminoglycans. Inhibition rate constants for these exosite-1 (Q24A, K65A, H66A, Y71A) thrombin mutants (0.02-0.38 × 108 M-1 min-1 for HCII-heparin when compared with 2.36 × 108 M-1 min-1 with wild-type thrombin and 0.03-0.53 × 108 M-1 min-1 for HCII-denaatan sulfate when compared with 5.23 × 108 M-1 min-1 with wild-type thrombin) confirmed that the structural integrity of thrombin exosite-1 is critical for optimal HCII-thrombin interactions in the presence of glycosaminoglycans. However, our results are also consistent for HCII-glycosaminoglycan-thrombin ternary complex formation. Ten residues surrounding the active site of thrombin were implicated in HCII interactions. Four mutants (Asp51, Lys 52, Lys145/ Thr147/Trp148, Asp 234) showed normal increased rates of inhibition by HCII-glycosaminoglycans, whereas four mutants (Trp50, Glu 202, Glu229, Arg233) remained resistant to inhibition by HCII with glycosaminoglycans. Using 11 exosite-2 thrombin mutants with 20 different mutated residues, we saw no major perturbations of HCII-glycosaminoglycan inhibition reactions. Collectively, our results support a "double bridge" mechanism for HCII inhibition of thrombin in the presence of glycosaminoglycans, which relies in part on ternary complex formation but is primarily dominated by an allosteric process involving contact of the "hirudin-like" domain of HCII with thrombin exosite-1.

UR - http://www.scopus.com/inward/record.url?scp=5644223097&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=5644223097&partnerID=8YFLogxK

U2 - 10.1074/jbc.M406716200

DO - 10.1074/jbc.M406716200

M3 - Article

C2 - 15292227

AN - SCOPUS:5644223097

VL - 279

SP - 43237

EP - 43244

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 41

ER -